Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
Filed with HKEX · Stock code 7630 · · 3 pages · English
IMPACT THERAPEUTICS IMPACT Therapeutics, Inc南京英派藥業股份有限公司 (A joint stock company established in the People’s Republic of China with limited liability) (Stock Code: 7630) VOLUNTARY ANNOUNCEMENT POSITIVE CHMP OPINION FOR SENAPARIB, AS POTENTIAL FIRST-LINE MAINTENANCE TREATMENT OF ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER This announcement is made by IMPACT Therapeutic
IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- 2026 Interim Report
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- Articles of association
- Next Day Disclosure Return
Later from IMPACT Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - poster presentation of latest clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707 at 2026 esmo congress
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics